Medically reviewed by Drugs.com. Last updated on Oct 31, 2020.
(e THAM byoo tole)
- Ethambutol HCl
- Ethambutol Hydrochloride
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Tablet, Oral, as hydrochloride:
Myambutol: 100 mg [DSC]
Myambutol: 400 mg [scored]
Generic: 100 mg, 400 mg
Brand Names: U.S.
- Antitubercular Agent
Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis
Widely throughout body; concentrated in kidneys, lungs, saliva, and red blood cells
CSF:blood level ratio: Normal meninges: 0%; Inflamed meninges: 25%
Hepatic (20%) to inactive metabolite
Urine (~50% as unchanged drug, 8% to 15% as metabolites); feces (~20% as unchanged drug)
Time to Peak
Serum: 2-4 hours
2.5-3.6 hours; End-stage renal disease: 7-15 hours
20% to 30%
Use: Labeled Indications
Tuberculosis: Treatment of pulmonary tuberculosis in conjunction with other antituberculosis agents.
Off Label Uses
Mycobacterium avium complex disease
Based on the Department of Health and Human Services (HHS) Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, ethambutol, in combination with other appropriate antimycobacterial drugs, is effective and recommended for the treatment and chronic maintenance therapy (secondary prophylaxis) of disseminated MAC disease in patients with HIV [HHS [OI adult 2020]].
Based on the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) Guideline for the Diagnosis, Treatment, and Prevention of Nontuberculosis Mycobacterial Disease, ethambutol, in combination with other appropriate antimycobacterial drugs, is effective and recommended for the treatment of MAC pulmonary and/or disseminated disease [ATS/IDSA [Griffith 2007]].
Nontuberculous mycobacterial disease (M. kansasii)
Data from a small prospective, single-arm study and a larger retrospective study support the use of ethambutol, in combination with clarithromycin and rifampin, in the treatment of susceptible Mycobacterium kansasii pulmonary disease [Shitrit 2006], [Griffith 2003]. Additional trials may be necessary to further define the role of ethambutol in this condition.
Based on the ATS/IDSA Guideline for the Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases ethambutol, in combination with rifampin and isoniazid, is effective and recommended for the treatment of susceptible M. kansasii pulmonary disease [ATS/IDSA [Griffith 2007]].
Hypersensitivity to ethambutol or any component of the formulation; optic neuritis (risk vs benefit decision); use in young children, unconscious patients, or any other patient who may be unable to discern and report visual changes
Mycobacterium avium complex (MAC) disease (off-label use): Oral:
Nodular/bronchiectatic disease: 25 mg/kg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and rifampin; continue treatment until patient is culture negative on therapy for 1 year. Note: Not recommended for severe or previously treated pulmonary disease (ATS/IDSA [Griffith 2007]).
Severe nodular/bronchiectatic or fibrocavitary disease: 15 mg/kg once daily in combination with daily macrolide (azithromycin or clarithromycin) and rifamycin (rifampin or rifabutin) therapy; continue treatment until patient is culture negative on therapy for 1 year. May also consider addition of 3 times weekly amikacin or streptomycin early in therapy. (ATS/IDSA [Griffith 2007]).
Disseminated disease in patients with HIV, treatment and chronic maintenance therapy: 15 mg/kg once daily in combination with a macrolide (azithromycin or clarithromycin); may discontinue when patient has completed ≥12 months of therapy, has no signs/symptoms of MAC disease, and has sustained (>6 months) CD4 count >100 cells/mm3 in response to ART. Note: Addition of a third or fourth drug should be considered for patients with advanced immunosuppression, high mycobacterial loads, or in the absence of effective ART (HHS [OI adult 2020]).
Nontuberculous mycobacterial disease (M. kansasii) (off-label use): Oral: 15 mg/kg/day in combination with rifampin and isoniazid or clarithromycin for a duration to include 12 months of culture-negative sputum (ATS/IDSA [Griffith 2007]; Shitrit 2006).
Tuberculosis (drug-susceptible): Oral: Note: Always administer in combination with other antitubercular drugs.
Dosing: Doses should be based on lean body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established):
Once-daily therapy: Note: The preferred frequency of administration is once daily; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative (ATS/CDC/IDSA [Nahid 2016]).
40 to 55 kg: 800 mg (14.5 to 20 mg/kg).
56 to 75 kg: 1,200 mg (16 to 21.4 mg/kg).
76 to 90 kg: 1,600 mg (17.8 to 21.1 mg/kg).
Three-times-weekly DOT (ATS/CDC/IDSA [Nahid 2016]):
40 to 55 kg: 1,200 mg (21.8 to 30 mg/kg).
56 to 75 kg: 2,000 mg (26.7 to 35.7 mg/kg).
76 to 90 kg: 2,400 mg (26.7 to 31.6 mg/kg).
Twice-weekly DOT (ATS/CDC/IDSA [Nahid 2016]):
40 to 55 kg: 2,000 mg (36.4 to 50 mg/kg).
56 to 75 kg: 2,800 mg (37.3 to 50 mg/kg).
76 to 90 kg: 4,000 mg (44.4 to 52.6 mg/kg).
Regimens: Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes ethambutol, followed by a continuation phase consisting of a 2-drug regimen (does not include ethambutol) of an additional 4 to 7 months; ethambutol frequency and dosing differs depending on treatment regimen selected; consult current Drug-sensitive TB guidelines (ATS/CDC/IDSA [Nahid 2016]).
Tuberculosis, drug resistant (alternative agent): Note: Expert consultation for optimal regimen and duration of treatment is advised (AST/CDC/ERS/IDSA [Nahid 2019]).
Low dose (companion drug): 15 mg/kg once daily (AST/CDC/ERS/IDSA [Nahid 2019]).
High dose (bacteriostatic drug): 25 mg/kg once daily (AST/CDC/ERS/IDSA [Nahid 2019]).
Refer to adult dosing.
Tuberculosis, active treatment (excluding meningitis): Note: Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations, as appropriate. Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for pulmonary tuberculosis consist of an initial 2-month intensive phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin. Ethambutol frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016])
ATS/CDC/IDSA Recommendations (ATS/CDC/IDSA [Nahid 2016]):
Once daily or 5-times-weekly (DOT):
Infants, Children, and Adolescents <15 years, weighing <40 kg: Oral: 20 mg/kg/dose once daily or 5-times-weekly DOT, suggested range: 15 to 25 mg/kg/dose
Children and Adolescents <15 years weighing ≥40 kg or Adolescents ≥15 years: Note: Doses should be based on lean body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established): Oral: Weight-band dosing for whole tablets:
40 to 55 kg: 800 mg (14.5 to 20 mg/kg/dose) once daily or 5-times-weekly (DOT)
56 to 75 kg: 1,200 mg (16 to 21.4 mg/kg/dose) once daily or 5-times-weekly (DOT)
76 to 90 kg: 1,600 mg (17.8 to 21.1 mg/kg/dose) once daily or 5-times-weekly (DOT)
Three-times-weekly DOT: Note: Although suggested dosing based on experience with twice-weekly regimen; experts suggest 3-times-weekly regimens are more effective than twice weekly DOT regimens; ethambutol-containing 3-times-weekly DOT may be used as part of an intensive phase; consult guidelines for specific information
Infants, Children, and Adolescents, weighing <40 kg: Oral: 50 mg/kg/dose 3-times-weekly
Children and Adolescents weighing ≥40 kg: Note: Doses should be based on lean body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established); Oral: Weight-band dosing for whole tablets:
40 to 55 kg: 1,200 mg (21.8 to 30 mg/kg/dose) 3-times-weekly
56 to 75 kg: 2,000 mg (26.7 to 35.7 mg/kg/dose) 3-times-weekly
76 to 90 kg: 2,400 mg (26.7 to 31.6 mg/kg/dose) 3-times-weekly
Twice weekly DOT: Note: Regimen not generally recommended; do not use in HIV patients or those with smear-positive and/or cavitary disease. This therapy should only be used following completion of a 2-week intensive phase once daily (or 5-times-weekly) regimen. Missed doses result in the equivalent of once-weekly dosing which has been shown to be inferior and is associated with treatment failure, relapse, and development of drug resistance.
Infants, Children, and Adolescents <15 years, weighing <40 kg: Oral: 50 mg/kg/dose twice weekly
Children and Adolescents <15 years weighing ≥40 kg or Adolescents ≥15 years: Note: Doses should be based on lean body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established); Oral: Weight-band dosing for whole tablets:
40 to 55 kg: 2,000 mg (36.4 to 50 mg/kg/dose) twice weekly
56 to 75 kg: 2,800 mg (37.3 to 50 mg/kg/dose) twice weekly
76 to 90 kg: 4,000 mg (44.4 to 52.6 mg/kg/dose) twice weekly
Mycobacterium avium complex (MAC) in HIV-exposed/-positive:
Infants and Children: Oral: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose; in combination with clarithromycin (or azithromycin); for severe disease add rifabutin (HHS [pediatric OI 2016])
Adolescents: Oral: 15 mg/kg/dose once daily in combination with clarithromycin (or azithromycin) (HHS [adult OI 2016])
Chronic suppressive therapy: Infants and Children: Oral: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose with clarithromycin (or azithromycin) with or without rifabutin (HHS [pediatric OI 2016])
Nontuberculous mycobacterial infection (eg, m. kansasii): Limited data available: Infants, Children, and Adolescents: 15 to 25 mg/kg/dose once daily; maximum dose: 2,500 mg/dose (Bradley 2016; Red Book [AAP] 2015)
Oral: Administer with or without food; if GI upset occurs, administer with food.
Store at controlled room temperature of 20°C to 25°C (68°F to 77°F).
Aluminum Hydroxide: May decrease the serum concentration of Ethambutol. Management: Avoid concurrent administration of ethambutol and aluminum hydroxide. If coadministration cannot be avoided administer ethambutol first and then wait at least 4 hours before administering aluminum hydroxide-containing products. Consider therapy modification
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Consider therapy modification
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Cardiovascular: Myocarditis, pericarditis
Central nervous system: Confusion, disorientation, dizziness, hallucination, headache, malaise, peripheral neuritis
Dermatologic: Dermatitis, erythema multiforme, exfoliative dermatitis, pruritus, skin rash
Endocrine & metabolic: Acute gout attack, hyperuricemia
Gastrointestinal: Abdominal pain, anorexia, gastric distress, nausea, vomiting
Hematologic & oncologic: Eosinophilia, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia
Hepatic: Abnormal hepatic function tests, hepatitis, hepatotoxicity (possibly related to concurrent therapy)
Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction (syndrome includes cutaneous reactions, eosinophilia, and organ-specific inflammation)
Neuromuscular & skeletal: Arthralgia
Ophthalmic: Color blindness, decreased visual acuity, optic neuritis, scotoma, visual disturbance (usually reversible with discontinuation; irreversible blindness has been described)
Respiratory: Pneumonitis, pulmonary infiltrates (with or without eosinophilia)
Concerns related to adverse effects:
• Hepatic toxicity: Has been reported, possibly due to concurrent therapy. Monitor liver function prior to and during treatment.
• Optic neuritis: May cause optic neuritis (unilateral or bilateral), resulting in decreased visual acuity or other vision changes. Discontinue promptly in patients with changes in vision, color blindness, or visual defects (effects normally reversible, but reversal may require up to a year). Irreversible blindness has been reported. Monitor visual acuity prior to and during therapy.
• Ocular disease: Evaluation of visual acuity changes may be more difficult in patients with cataracts, optic neuritis, diabetic retinopathy, and inflammatory conditions of the eye; consideration should be given to whether or not visual changes are related to disease progression or effects of therapy.
• Renal impairment: Use with caution in patients with renal impairment; dosage modification recommended. Monitor renal function prior to and during treatment.
• Pediatric: Use only in children whose visual acuity can accurately be determined and monitored (not recommended for use in children <13 years of age unless the benefit outweighs the risk).
Baseline and periodic (monthly) visual testing (Snellen test) and color discrimination tests (each eye individually, as well as both eyes tested together) in patients receiving >15 mg/kg/day; baseline and periodic renal, hepatic, and hematopoietic tests
Evaluate pregnancy status prior to treatment of multidrug-resistant tuberculosis in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment for multidrug-resistant tuberculosis (Esmail 2018).
Pregnancy Risk Factor
Ethambutol crosses the placenta (Shneerson 1979).
In one case report, ethambutol placental concentrations were similar to those in the maternal plasma. Ethambutol was also present in the cord blood and amniotic fluid (Shneerson 1979).
Ophthalmic abnormalities have been reported in infants born to women receiving ethambutol as a component of antituberculosis therapy. Active tuberculosis infection is also associated with adverse fetal outcomes including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020) as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).
Due to the risks of untreated tuberculosis, ethambutol is recommended as part of the initial treatment regimen of drug-susceptible active tuberculosis when the probability of maternal disease is moderate to high (ATS/CDC/IDSA [Nahid 2016]).
Ethambutol may also be used to treat multidrug-resistant tuberculosis. The treatment of multidrug-resistant tuberculosis in pregnant patients should be individualized; evidence to support a specific regimen is not available (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020).
Pregnancy-induced physiologic changes do not alter the pharmacokinetic properties of ethambutol in a clinically significant way; dose adjustment is not needed in pregnant patients (Abdelwahab 2020).
What is this drug used for?
• It is used to treat TB (tuberculosis).
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Lack of appetite
• Loss of strength or energy
• Abdominal pain
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin.
• Sore throat
• Sensing things that seem real but are not
• Joint pain
• Joint swelling
• Numbness or tingling of hands or feet
• Vision changes
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about ethambutol
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 2 Reviews
- Drug class: miscellaneous antituberculosis agents
Other brands: Myambutol